Physician profile
Su Zhan
NPI 1053553701
$9,079.19
in general payments reported to CMS, 2019-2025
21 companies · $2,072 in 2025
The $2,072 reported for 2025 was more than what 94% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $682 · 2020: $279 · 2021: $432 · 2022: $2,048 · 2023: $1,207 · 2024: $2,359 · 2025: $2,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,682 · Travel and Lodging: $1,957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,681.65 |
| Travel and Lodging | $1,956.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,745.56 | 2021-2025 | Proclaim, Octrode, Eterna |
| Curonix LLC | $983.61 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Boston Scientific Corporation | $841.18 | 2021-2023 | Wavewriter Alpha Prime 16 |
| Scilex Pharmaceuticals INC. | $439.37 | 2019-2025 | Ztlido |
| Horizon Therapeutics Plc | $301.54 | 2019-2021 | |
| Abbvie INC. | $171.05 | 2019-2025 | |
| Sentynl Therapeutics, INC. | $108.11 | 2019 | |
| Supernus Pharmaceuticals, INC. | $68.69 | 2019-2021 | |
| Spr Therapeutics, INC | $58.32 | 2025 | Sprint Pns System |
| Shionogi INC | $54.05 | 2019 | |
| Arbor Pharmaceuticals, INC. | $49.05 | 2019 | |
| Zyla Life Sciences, INC. | $40.06 | 2019-2020 | |
| Pfizer INC. | $37.54 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $37.52 | 2019-2020 | |
| Medtronic, INC. | $29.92 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $24.00 | 2023 | Belbuca |
| Fidia Pharma USA INC. | $22.00 | 2022 | |
| Galderma Laboratories, L.P. | $19.82 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $19.26 | 2025 | |
| Saluda Medical Americas, INC. | $15.49 | 2023 | Evoke Scs |
| Assertio Therapeutics, INC. | $13.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Su Zhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.